A multicenter, open-label, non-controlled, dose-escalation study in patients with relapsed/refractory multiple myeloma and non-Hodgkin's lymphoma (ONO-7705-01)

ONO PHARMACEUTICAL CO.,LTD.1 site18 target enrollmentStarted: TBDLast updated: October 14, 2020

Trial Snapshot

No summary available.

Study Type: Interventional
Intervention Model: Multicenter, Open-label, Non-controlled, Dose-escalation Study
Primary Purpose: Treatment Purpose

•Patients who are able to stay in hospital from a day before starting the study drug of the first course until the end of the relevant tests on Day 28
•Patients with relapsed/refractory MM or NHL
•Patients who have received two or more lines of therapies for MM or NHL

•Patients with plasma cell leukemia (defined as a peripheral blood plasma cell count > 2.0*10^9/L by the standard classification method)
•Patients with primary amyloidosis
•Patients with POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes)
•Patients with acute lymphocytic leukemia
•Patients with lymphoblastic lymphoma
•Patients with Burkitt's lymphoma or Richter's Syndrome

safety tolerability of ONO-7705 in relapsed/refractory MM and NHL patients

No secondary outcomes reported

Sponsor

ONO PHARMACEUTICAL CO.,LTD.

Loading locations...